PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29688202-1	2018	The purpose of the study was to evaluate efficacy of Diosmin (Phlebodia 600, Innothera, France) in treatment of patients presenting with class C0s-C3 chronic venous diseases (CVD) according to the CEAP classification.	Diosmin	53-60	biogenesis of lysosomal organelles complex 1 subunit 2	Homo sapiens	197-201	
19245142-16	2008	CONCLUSION: Administration of semisynthetic diosmin during 30 days results in significant improvement of clinical signs, quality of life and CEAP stage of HVI.	Diosmin	44-51	biogenesis of lysosomal organelles complex 1 subunit 2	Homo sapiens	141-145	
17053765-1	2006	The study was held to assess clinical effectiveness of coaggregated semisynthetic Diosmin (Phlebodia 600) for patients with II-III CEAP classes of chronic venous insufficiency (CVI), caused by lower limb variceal diseases.	Diosmin	82-89	biogenesis of lysosomal organelles complex 1 subunit 2	Homo sapiens	131-135